Adel, Inc.

3:15 PM - 3:30 PM (PDT), Monday, June 13, 2022
Adel is a Korean biotech company developing novel innovative approach to neurodegenerative diseases like Alzheimer and Parkinson diseases. ADTAC (Authophagy Degradation TArgeting Chimera) is also one of the main strategy. Adel is seeking new opportunities for co-development and in/out lincensing.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Manager of Strategy and Licensing
ADEL, Inc.